SCHEMBL3334533

SCHEMBL3334533

Cc1cccc2c(=O)n(-c3ccc(F)c(F)c3F)c(=S)[nH]c12

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE7A Q13946 5/20 0.69
CA12 O43570 8/20 0.54
CA1 P00915 8/20 0.54
CA2 P00918 8/20 0.54
CA9 Q16790 7/20 0.54
KDM4E B2RXH2 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
NPC1 O15118 1/20 0.40
MAPT P10636 1/20 0.40
RAB9A P51151 1/20 0.40
HSD17B10 Q99714 1/20 0.40
ALDH1A1 P00352 3/20 0.39
KMT2A Q03164 1/20 0.39
LMNA P02545 2/20 0.39
PPARG P37231 2/20 0.39
RXFP1 Q9HBX9 2/20 0.39
NR2E3 Q9Y5X4 2/20 0.39
NCOR2 Q9Y618 2/20 0.39
NPSR1 Q6W5P4 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30837780 1.00 PDE7A (0.69) PDE7ACA12CA1CA2CA9
SCHEMBL3336461 0.82 PDE7A (1.00) PDE7ACA12CA1CA2CA9
SCHEMBL30837960 0.82 PDE7A (1.00) PDE7ACA12CA1CA2CA9
SCHEMBL299355 0.79 PDE7A (1.00) PDE7ACA12CA1CA2CA9
SCHEMBL31597447 0.78 PDE7A (0.70) PDE7ACA12CA1CA2CA9
SCHEMBL30837827 0.77 PDE7A (1.00) PDE7ACA12CA1CA2CA9
SCHEMBL844874 0.77 PDE7A (1.00) PDE7ACA12CA1CA2CA9
SCHEMBL31597397 0.76 CA12 (0.70) PDE7ACA12CA1CA2CA9
SCHEMBL31597470 0.72 CA12 (0.65) PDE7ACA12CA1CA2CA9
SCHEMBL29832061 0.71 PDE7A (0.64) PDE7ACA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100152213-A1 COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) 2010-06-17 US claimed
EP-2130823-A1 COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF Consejo Superior De Investigaciones Científicas (ES) 2009-12-09 EP claimed
US-20260060970-A1 Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance MITODICURE GMBH (DE) 2026-03-05 US disclosed
US-20100152213-A1 COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) 2010-06-17 US disclosed
US-20100152213-A1 COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (ES) 2010-06-17 US disclosed
EP-2130823-A1 COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF Consejo Superior De Investigaciones Científicas (ES) 2009-12-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260060970-A1 Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance PDE5A, PDE4C, PDE12 PDE7A 5/4885CA12 1376/4885CA1 2358/4885
US-20100152213-A1 COMPOUND THAT IS A DUAL INHIBITOR OF ENZYMES PDE7 AND/OR PDE4, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF PDE4B, PDE7B, PDE12 PDE7A 6/4885CA12 1678/4885CA1 1199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.